#1 Clinical Trials Search in Europe

(2R)-2-[[2-Amino-5-[(1S)-1-Phenylethyl]Sulfanyl-[1,3]Thiazolo[4,5-D]Pyrimidin-7-Yl]Amino]-4-Methylpentan-1-Ol Hydrochloride

This article discusses a clinical trial investigating the use of KAND567, a new drug containing (2R)-2-[[2-Amino-5-[(1S)-1-Phenylethyl]Sulfanyl-[1,3]Thiazolo[4,5-D]Pyrimidin-7-Yl]Amino]-4-Methylpentan-1-Ol Hydrochloride, in combination with carboplatin for treating recurrent ovarian, fallopian tube, or primary peritoneal cancer. The study aims to assess the safety, tolerability, and potential effectiveness of this combination therapy in women with these types of recurring cancers.

Table of Contents

What is KAND567?

KAND567 is a new medication being studied for the treatment of certain types of cancer. Its full chemical name is (2R)-2-[[2-AMINO-5-[(1S)-1-PHENYLETHYL]SULFANYL-[1,3]THIAZOLO[4,5-D]PYRIMIDIN-7-YL]AMINO]-4-METHYLPENTAN-1-OL HYDROCHLORIDE. It’s also known as a fractalkine receptor antagonist, which describes how it works in the body[1].

Medical Conditions Treated

KAND567 is being studied for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. These are types of cancers that affect a woman’s reproductive system and abdomen[1].

  • Ovarian cancer: A cancer that begins in the ovaries, which are part of a woman’s reproductive system.
  • Fallopian tube cancer: A rare cancer that develops in the tubes that connect the ovaries to the uterus.
  • Primary peritoneal cancer: A rare cancer that develops in the peritoneum, the tissue lining the abdominal wall and covering the organs in the abdomen.

The study focuses on cancers that have come back after previous treatment, which is what “recurrent” means in this context[1].

How KAND567 Works

KAND567 is a fractalkine receptor antagonist. While the exact mechanism isn’t fully explained in the study information, fractalkine receptor antagonists generally work by blocking certain signals in the body that can contribute to cancer growth and spread[1].

Current Research

KAND567 is currently being studied in a clinical trial called KANDOVA. This is a Phase Ib/IIa study, which means it’s in the early stages of testing in humans. The study has two main goals[1]:

  1. To evaluate the safety and tolerability of KAND567 when used in combination with another cancer drug called carboplatin.
  2. To determine the best dose of KAND567 to use in future studies.

The study is also looking at how well the combination of KAND567 and carboplatin works in treating these cancers[1].

Eligibility for the Study

The study has specific criteria for who can participate. Some key points include[1]:

  • Participants must be at least 18 years old
  • They must have a confirmed diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  • The cancer must have returned after previous treatment with platinum-based chemotherapy
  • Participants must be in generally good health, with adequate organ function

There are also several conditions that would prevent someone from participating in the study, such as certain other medical conditions or use of specific medications[1].

Potential Benefits

While it’s too early to know for sure, the researchers hope that KAND567, when combined with carboplatin, might provide benefits such as[1]:

  • Improved response to treatment (shrinking or slowing growth of tumors)
  • Longer time before the cancer progresses
  • Improved overall survival
  • Reduction in pain symptoms

Safety and Side Effects

One of the main goals of this study is to evaluate the safety of KAND567. The researchers will be closely monitoring for any side effects or adverse events. As this is an early-stage study, not all potential side effects are known yet[1].

Administration

KAND567 is given as a hard capsule that is taken by mouth. It’s being studied in combination with carboplatin, which is typically given through an intravenous (IV) infusion[1].

Aspect Details
Study Type Phase Ib/IIa clinical trial
Drug Tested KAND567 (containing (2R)-2-[[2-Amino-5-[(1S)-1-Phenylethyl]Sulfanyl-[1,3]Thiazolo[4,5-D]Pyrimidin-7-Yl]Amino]-4-Methylpentan-1-Ol Hydrochloride)
Combination Therapy KAND567 with carboplatin
Target Condition Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Primary Objectives Evaluate safety, tolerability, and determine recommended Phase II dose
Secondary Objectives Assess overall response rate, progression-free survival, and effects on pain symptoms
Key Eligibility Criteria Women aged 18+, specific cancer types, prior platinum-based chemotherapy, adequate organ function
Main Exclusion Criteria Other cancer types, recent major surgery, active infections, brain metastases

FAQ

  • What is the purpose of this clinical trial? The main purpose of this trial is to evaluate the safety and tolerability of KAND567 when combined with carboplatin therapy for treating recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also aims to determine the recommended dose for future Phase II studies.
  • Who can participate in this trial? Women aged 18 or older with recurrent high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer may be eligible. Participants must have had prior platinum-based chemotherapy and meet specific criteria regarding their disease progression and overall health status.
  • How is the drug KAND567 administered? KAND567 is administered orally in the form of hard capsules. It is given in combination with carboplatin therapy as part of the treatment regimen.
  • What are the main outcomes being measured in this trial? The primary outcomes include the occurrence of adverse events, serious adverse events, and dose-limiting toxicities. The study will also assess the overall response rate, progression-free survival, and changes in pain scores among participants.
  • How long does the trial last? The exact duration of the trial is not specified in the provided information. However, the study includes assessments at various time points, including Weeks 12 and 18, and overall survival will be evaluated at the end of the study.

Ongoing Clinical Trials on (2R)-2-[[2-Amino-5-[(1S)-1-Phenylethyl]Sulfanyl-[1,3]Thiazolo[4,5-D]Pyrimidin-7-Yl]Amino]-4-Methylpentan-1-Ol Hydrochloride

  • Study on the Safety and Tolerability of KAND567 and Carboplatin for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Norway Sweden

Glossary

  • Carboplatin: A chemotherapy drug commonly used to treat various types of cancer, including ovarian cancer.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Epithelial ovarian cancer: The most common type of ovarian cancer that begins in the cells covering the outer surface of the ovary.
  • GCIG CA 125 criteria: Guidelines set by the Gynecologic Cancer Intergroup for measuring CA 125, a protein that can indicate the presence of ovarian cancer.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Recommended Phase II Dose (RPIID): The dose of a drug determined to be safe and potentially effective for use in larger Phase II clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-kand567-and-carboplatin-for-women-with-recurrent-ovarian-fallopian-tube-or-primary-peritoneal-cancer/